腫瘍病理鑑別診断アトラス 乳癌 第3版

出版社: 文光堂
著者:
発行日: 2022-11-07
分野: 臨床医学:基礎  >  臨床病理学
ISBN: 9784830622625
シリーズ: 腫瘍病理鑑別診断アトラス
電子書籍版: 2022-11-07 (第3版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:4~8営業日

17,600 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

17,600 円(税込)

商品紹介

腫瘍病理鑑別診断シリーズ「乳癌」,待望の第3版.2019年にはWHO分類第5版が発行され,遺伝子検査やPD-L1評価が行われるようになり,さらに分子標的治療が導入されるなど,乳腺腫瘍病理を取り巻く環境は日々変化している.そうした状況を踏まえ,乳腺腫瘍病理のエキスパートが精選した病理写真とともに,定義や概念,診断上の要点を解説する.組織の形態学的特徴とともに,免疫組織化学の適切な利用法や,臨床との連携に欠かせない広がり診断および治療効果判定,病理診断報告様式について解説した.

目次

  • 第1部 検鏡前の確認事項
     I.乳腺腫瘍の組織型分類:乳癌取扱い規約 第18版(2018年)とWHO分類 第5版(2019年)の概要
     II.病理検体の取扱い方

    第2部 組織型と診断の実際
     I.上皮性腫瘍
      1.良性上皮増殖性病変および境界病変
      2.腺症およびその関連病変
      3.腺腫
      4.上皮・筋上皮性腫瘍
      5.乳頭状腫瘍
      6.小葉性腫瘍
      7.非浸潤性乳管癌
      8.浸潤性乳管癌
      9.微小浸潤癌
      10.特殊型乳癌
      (1)浸潤性小葉癌
      (2)管状癌
      (3)篩状癌
      (4)粘液癌
      (5)浸潤性微小乳頭癌
      (6)アポクリン癌
      (7)化生癌
      (8)神経内分泌腫瘍
      (9)腺様囊胞癌および他の唾液腺型乳癌
      (10)分泌癌
      (11)その他のまれな乳癌
     II.線維上皮性腫瘍(結合織性および上皮性混合腫瘍)
      1.線維腺腫
      2.葉状腫瘍
     III.乳頭部の腫瘍
     IV.間葉系腫瘍
     V.血液・リンパ球系腫瘍
     VI.男性乳腺疾患
     VII.その他の腫瘍様病変
     VIII.転移性乳腺腫瘍

    第3部 鑑別ポイント
     I.上皮性病変における良悪性鑑別のための要点
     II.針生検における組織型鑑別の注意点
     III.組織型鑑別のための免疫組織化学的検索の要点

    第4部 臨床との連携
     I.遺伝性乳癌の臨床病理
     II.乳癌の悪性度評価
     III.乳癌のバイオマーカー検索
     IV.病理診断をふまえた乳癌の治療
     V.術中・術後の乳癌の広がり診断
     VI.病理学的治療効果判定
     VII.手術標本における病理診断報告書の記載法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

P.8 掲載の参考文献
1) WHO Classification of Tumours Editorial Board(ed):WHO Classification of Tumours, Breast Tumours(5th ed. ), IARC, Lyon, 2019
2) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018
3) Lakhani SR, Ellis IO, Schnitt SJ, et al(eds):WHO Classification of Tumours of the Breast(4th ed. ), IARC, Lyon, 2012
4) Yang H, Ye D, Guan KL, et al:IDH1 and IDH2 mutations in tumorigenesis:mechanistic insights and clinical perspectives. Clin Cancer Res 18:5562-5571, 2012
5) Alsadoun N, MacGrogan G, Truntzer C, et al:Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast:a comparative study of 9 additional cases. Mod Pathol 31:1367-1380, 2018
6) Chiang S, Weigelt B, Wen HC, et al:IDH2 mutations define a unique subtype of breast cancer with altered nuclear polarity. Cancer Res 76:7118-7129, 2016
7) Tavassoli FA, Devilee P(eds):WHO Classification of Tumours, Pathology and Genetics, Tumours of the Breast and Female Genital Organs(3rd ed. ), IARC, Lyon, 2003
8) Reis-Filho JS, Lakhani SR:The diagnosis and management of pre-invasive breast disease:genetic alterations in pre-invasive lesions. Breast Cancer Res 5:313-319, 2003
9) Boecker W, Moll R, Dervan P, et al:Usual ductal hyperplasia of the breast is a committed stem(progenitor)cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 198:458-467, 2002
11) Abdel-Fatah TMA, Powe DG, Hodi Z, et al:High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 31:417-426, 2007
12) Marucci G, Betts CM, Golouh R, et al:Toker cells are probably precursors of Paget cell carcinoma:a morphological and ultrastructural description. Virchows Arch 441:117-123, 2002
P.16 掲載の参考文献
1) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018
2) 日本病理学会(編):ゲノム研究用・診療用病理組織検体取扱い規程, 羊土社, 2019, pp129-157
3) Khoury T, Sait S, Hwang H, et al:Delay to formalin fixation effect on breast biomarkers. Mod Pathol 22:1457-1467, 2009
4) Arima N, Nishimura R, Osako T, et al:The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index. J Clin Pathol 69:255-259, 2016
5) 東 学, 山下和也, 石田克成ほか:本邦における病理組織検体固定手技の実態調査-日臨技精度管理調査アンケートによる報告-. 医学検査 69:660-670, 2020
6) 唐 小燕, 小林博子, 増田しのぶ:切り出しのキモ-私はここをこう切っている-乳腺. 病理と臨床 38:745-750, 2020
7) 日本乳癌学会(編):乳癌診療ガイドライン2 疫学・診断編 2018年版, 金原出版, 2018
P.24 掲載の参考文献
1) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018
2) Schnitt SJ, Purdie CA, Weaver DL:Usual ductal hyperplasia. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp13-14
3) London SJ, Connolly JL, Schnitt SJ, et al:A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941-944, 1992(Erratum in:JAMA 267:1780, 1992)
4) Harada O, Hoe R, Lin J, et al:Intranuclear inclusions in epithelial cells of benign proliferative breast lesions. J Clin Pathol 64:776-780, 2011
5) Moriya T, Kozuka Y, Kanomata N, et al:The role of immunohistochemistry in the differential diagnosis of breast lesions. Pathology 41:68-76, 2009
6) Jahn SW, Kashofer K, Thuringer A, et al:Mutation profiling of usual ductal hyperplasia of the breast reveals activating mutations predominantly at different levels of the PI3K/AKT/mTOR pathway. Am J Pathol 186:15-23, 2016
7) Pena A, Shah SS, Fazzio RT, et al:Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia. Breast Cancer Res Treat 164:295-304, 2017
8) Zhang C, Wang EY, Liu F, et al:Type of architecture, presence of punctate necrosis, and extent of involvement in atypical ductal hyperplasia can predict the diagnosis of breast carcinoma on excision:a clinicopathologic study of 143 cases. Int J Surg Pathol 29:716-721, 2021
9) Hartmann LC, Sellers TA, Frost MH, et al:Benign breast disease and the risk of breast cancer. N Engl J Med 353:229-237, 2005
10) Hartmann LC, Radisky DC, Frost MH, et al:Understanding the premalignant potential of atypical hyperplasia through its natural history. A longitudinal cohort study. Cancer Prev res(Phila) 7:211-217, 2014
11) Allison KH, Collins LC, Moriya T, et al:Atypical ductal hyperplasia. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp18-21
12) Page DL, Dupont WD, Rogers LW, et al:Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer. 55:2698-2708, 1985
13) Tavassoli FA, Norris HJ:A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast. Cancer 65:518-529, 1990
14) Kader T, Hill P, Rakha EA, et al:Atypical ductal hyperplasia:update on diagnosis, management, and molecular landscape. Breast Cancer Res 20:39, 2018
15) Danforth DN:Molecular profile of atypical hyperplasia of the breast. Breast Cancer Res Treat 167:9-29, 2018
16) Moriya T, Kasami M, Akiyama F, et al:A proposal for the histopathological diagnosis of ductal carcinoma in situ of the breast. Breast Cancer 7:321-325, 2000
17) Makretsov N:Now, later of never:multicenter randomized controlled trial call--is surgery necessary after atypical breast core biopsy results in mammographic screening settings? Int J Surg Oncol 2015:192579, 2015
18) Schnitt SJ, Morris EA, Vincent-Salomon A:Columnar cell lesions, including flat epithelial atypia. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp15-17
19) Said SM, Visscher DW, Nassar A, et al:Flat epithelial atypia and risk of breast cancer:a Mayo cohort study. Cancer 121:1548-1555, 2015
20) American Society of Breast Surgeons:Official statement. Consensus guideline on concordance assessment of image-guided breast biopsies and management of borderline or high-risk lesions, 2016. https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Concordance-Assessment-of-Image-Guided-Breast-Biopsies.pdf(2022年9月閲覧)
21) Collins LC:Precursor lesions of the low-grade breast neoplasia pathway. Surg Pathol Clin 11:177-197, 2018
22) Brandt SM, Young GQ, Hoda SA:The "Rosen triad":tubular carcinoma, lobular carcinoma in situ, and columnar cell lesions. Adv Anat Pathol 15:140-146, 2008
23) Hennessy G, Boland MR, Bambrick M, et al:Value of long-term follow-up in surgically excised lesions of uncertain malignant potential in the breast-Is 5 years necessary? Clin Breast Cancer, 2022, doi:10.1016/j.clbc.2022.05.009. online ahead of print
P.30 掲載の参考文献
1) WHO Classification of Tumours Editorial Board(ed):WHO Classification of Tumours, Breast Tumours(5th ed. ), IARC, Lyon, 2019
2) Oiwa M, Endo T, Ichihara S, et al:Sclerosing adenosis as a predictor of breast cancer bilaterality and multicentricity. Virchows Arch 467:71-78, 2015
3) Visscher DW, Nassar A, Degnim AC, et al:Sclerosing adenosis and risk of breast cancer. Breast Cancer Res Treat 144:205-212, 2014
4) Winham SJ, Mehner C, Heinzen EP, et al:NanoStringbased breast cancer risk prediction for women with sclerosing adenosis. Breast Cancer Res Treat 166:641-650, 2017
5) Wells CA, McGregor IL, Makunura CN, et al:Apocrine adenosis:a precursor of aggressive breast cancer? J Clin Pathol 48:737-742, 1995
6) Geyer FC, Lacroix-Triki M, Colombo PE, et al:Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. Histopathology 60:E115-130, 2012
7) Taylor HB, Norris HJ:Epithelial invasion of nerves in benign diseases of the breast. Cancer 20:2245-2249, 1967
8) Moritani S, Ichihara S, Hasegawa M, et al:Topographical, morphological and immunohistochemical characteristics of carcinoma in situ of the breast involving sclerosing adenosis. Two distinct topographical patterns and histological types of carcinoma in situ. Histopathology 58:835-846, 2011
9) O'Malley FP, Bane AL:The spectrum of apocrine lesions of the breast. Adv Anat Pathol 11:1-9, 2004
P.34 掲載の参考文献
1) Esposito NN:Fibroepithelial lesions. in Dabbs DJ(ed):"Breast Pathology"(2nd ed. ), Elsevier, Philadelphia, 2017, pp263-287
2) Bezic J, Karaman I, Sundov D:Combined fibroadenoma and tubular adenoma of the breast:Rare presentation that confirms common histogenesis. Breast J 21:309-311, 2015
3) Azzopardi JG, Salm R:Ductal adenoma of the breast:A lesion which can mimic carcinoma. J Pathol 144:15-23, 1984
4) 森谷鈴子:adenomas. 病理と臨床 39:340-344, 2021
5) Sengupta S, Pal S, Biswas BK, et al:Preoperative diagnosis of tubular adenoma of breast-10 years of experience. N Am J Med Sci 6:219-223, 2014
6) Zhu D, Qian HS, Han HX, et al:An unusual magnetic resonance imaging of a giant cystic volume of tubular adenoma of the breast. Breast J 23:225-226, 2017
7) Efared B, Sidibe IS, Abdoulaziz S, et al:Tubular adenoma of the breast:A clinicopathologic study of a series of 9 cases. Clin Med Insights Pathol 11:1-5, 2018
8) Szabo J, Garcia D, Ciomek N, et al:Spuriously aggressive features of a lactating adenoma prompting repeated biopsies. Radiol Case Rep 12:215-218, 2017
9) Teng CY, Diego EJ:Case report of a large lactating adenoe ma with rapid antepartum enlargement. Int J Surg Case Rep 20:127-129, 2016
10) Heymann JJ, Halligan AM, Hoda SA, et al:Fine needle aspiration of breast masses in pregnant and lactating women:experience with 28 cases emphasizing Thinprep findings. Diagn Cytopathol 43:188-194, 2015
11) Saglam A, Can B:Coexistence of lactating adenoma and invasive ductal adenocarcinoma of the breast in a pregnant woman. J Clin Pathol 58:87-89, 2005
12) Lammie GA, Millis RR:Ductal adenoma of the breast--a review of fifteen cases. Hum Pathol 20:903-908, 1989
13) Volckmar AL, Leichsenring J, Flechtenmacher C, et al:Tubular, lactating, and ductal adenomas are devoid of MED12 exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway. Genes Chromosomes Cancer 56:11-17, 2017
P.39 掲載の参考文献
1) Cima L, Kaya H, Marchio C, et al:Triple-negative breast carcinomas of low malignant potential:review on diagnostic criteria and differential diagnoses. Virchows Arch 480:109-126, 2022
2) Rakha E, Tan PH, Ellis I, et al:Adenomyoepithelioma of the breast:a proposal for classification. Histopathology 79:465-479, 2021
3) Tan PH, Ellis IO, Foschini MP, et al:Epithelial-myoepithelial tumours. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp39-48
4) Moritani S, Ichihara S, Yatabe Y, et al:Immunohistochemical expression of myoepithelial markers in adenomyoepithelioma of the breast:a unique paradoxical staining pattern of high-molecular weight cytokeratins. Virchows Arch 466:191-198, 2015
5) Geyer FC, Li A, Papanastasiou AD, et al:Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. Nat Commun 9:1816, 2018
P.48 掲載の参考文献
1) Intraductal papillary lesions. in Lakhani SR, Ellis IO, Schnitt SJ, et al(eds):"WHO Classification of Tumours of the Breast"(4th ed. ), IARC, Lyon, 2012, pp99-109
2) Brogi E, Horii R, Mac Grogan G, et al:Papillary neoplasms. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp49-67
3) 山口倫, 三原勇太郎, 矢野博久:乳腺腫瘍-WHO分類 第5版改訂のポイント-Papillary neoplasms. 病理と臨床 39:351-358, 2021
4) Yamaguchi R, Horii R, Maki K, et al:Carcinoma in a solitary intraductal papilloma of the breast. Pathol Int 59:185-187, 2009
5) Moritani S, Ichihara S, Hasegawa M, et al:Uniqueness of ductal carcinoma in situ of the breast concurrent with papilloma:implications from a detailed topographical and histopathological study of 50 cases treated by mastectomy and wide local excision. Histopathology 63:407-417, 2013
6) Yamaguchi R, Tanaka M, Tse GM, et al:Management of breast papillary lesions diagnosed in ultrasound-guided vacuum-assisted and core needle biopsies. Histopathology 66:565-576, 2015
7) Yamaguchi R, Tanaka M, Tse GM, et al:Broad fibrovascular cores may not be an exclusively benign feature in papillary lesions of the breast:a cautionary note. J Clin Pathol 67:258-262, 2014
8) Rakha EA, Varga Z, Elsheik S, et al:High-grade encapsulated papillary carcinoma of the breast:an under-recognized entity. Histopathology 66:740-746, 2015
P.52 掲載の参考文献
1) Shin SJ, Chen YY, Decker T, et al:Non-invasive lobular neoplasia. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp68-74
2) Hoda SA, Brogi E, Koerner FC, et al:Rosen's Breast Pathology(5th ed. ), Wolters Kluwer, Philadelphia, 2021, pp886-944
3) National Comprehensive Cancer Network:NCCN Guidelines. http://nccn.org/guidelines/category_1(2022年9月閲覧)
4) Wen HY, Brogi E:Lobular carcinoma in situ. Surg Pathol Clin 11:123-145, 2018
5) Lee JY, Schizas M, Geyer FC, et al:Lobular carcinoma in situ display intralesion genetic heterogeneity and clonal evolution in the progression to invasive lobular carcinoma. Clin Cancer Res 25:674-686, 2019
P.61 掲載の参考文献
1) Sheaffer WW, Gray RJ, Wasif N, et al:Predictive factors of upstaging DCIS to invasive carcinoma in BCT vs mastectomy. Am J Surg 217:1025-1029, 2019
2) Qian L, Lv Z, Zhang K, et al:Application of deep learning to predict underestimation in ductal carcinoma in situ of the breast with ultrasound. Ann Transl Med 9:295, 2021
3) Gilleard O, Goodman A, Cooper M, et al:The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol 6:61, 2008
4) 日本乳癌学会:全国乳がん患者登録調査報告 第49号2018年次症例
5) Sagara Y, Mallory MA, Wong S, et al:Survival benefit of breast surgery for low-grade ductal carcinoma in situ:a population-based cohort study. JAMA Surg 150:739-745, 2015
6) 日本臨床腫瘍研究グループ, 乳がんグループ:エストロゲン受容体陽性・低リスク非浸潤性乳管癌に対する非切除+内分泌療法の有用性に関する単群検証的試験実施計画書ver. 1.2.0. http://www.jcog.jp/document/1505.pdf(2022年5月閲覧)
7) Consensus conference on the classification of ductal carcinoma in situ. Hum Pathol 28, 1221-1225, 1997
8) Silverstein MJ, Lagios MD, Craig PH, et al:A prognostic index for ductal carcinoma in situ of the breast. Cancer 77:2267-2274, 1996
9) Maeda I, Tajima S, Ariizumi Y, et al:Can synaptophysin be used as a marker of breast cancer diagnosed by core-needle biopsy in epithelial proliferative diseases of the breast? Pathol Int 66:369-375, 2016
10) Wang Y, Zhu JF, Liu YY, et al:An analysis of cyclin D1, cytokeratin 5/6 and cytokeratin 8/18 expression in breast papillomas and papillary carcinomas. Diagn Pathol 8:8, 2013
11) Tsuda H, Uei Y, Fukutomi T, et al:Different incidence of loss of heterozygosity on chromosome 16q between intraductal papilloma and intracystic papillary carcinoma of the breast. Jpn J Cancer 85:992-996, 1994
12) Buerger H, Otterbach F, Simon R, et al:Comparative ge-nomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol 187:396-402, 1999
13) Kaur H, Mao S, Shah S, et al:Next-generation sequencing:a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ. Expert Rev Mol Diagn 13:151-165, 2013
14) Kim SY, Jung SH, Kim MS, et al:Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer. Oncotarget 6:7597-7607, 2015
15) Cheng E, D'Alfonso T, Patel A, et al:Mammary juvenile papillomatosis("Swiss cheese"disease):study of 121 cases reiterates need for long-term follow-up. Breast J 24:1136-1137, 2018
16) D'Alfonso TM, Pareja F, Da Cruz Paula A, et al:Wholeexome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. J Pathol Clin Res 7:113-120, 2021
17) Nagasawa S, Kuze Y, Maeda I, et al:Genomic profiling reveals heterogeneous populations of ductal carcinoma in situ of the breast. Commun Biol 4:438, 2021
P.72 掲載の参考文献
1) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018
2) WHO Classification of Tumours Editorial Board(ed):WHO Classification of Tumours, Breast Tumours(5th ed. ), IARC, Lyon, 2019, pp82-109
3) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第17版, 金原出版, 2012
4) 徳永えり子:内因性サブタイプから臨床的サブタイプ(IHC法によるサブタイプ)への変遷. 津田 均, 木下貴之, 田村研治(編):乳癌診療のための分子病理エッセンシャル, 南山堂, 2016, pp120-129
5) Hayashi N, Kumamaru H, Isozumi U, et al:Annual report of the Japanese Breast Cancer Registry for 2017. Breast Cancer 27:803-809, 2020
7) De Schepper M, Vincent-Salomon A, Christgen M, et al:Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer. Mod Pathol, 2022, doi:10.1038/s41379-022-01135-2. online ahead of print
8) Sasaki Y, Tsuda H, Ueda S, et al:Histological differences between invasive ductal carcinoma with a large central acellular zone and matrix-producing carcinoma of the breast. Pathol Int 59:390-394, 2009
P.76 掲載の参考文献
1) WHO Classification of Tumours Editorial Board(ed):WHO Classification of Tumours, Breast Tumours(5th ed. ), IARC, Lyon, 2019, pp110-113
2) Brierley JD, Gospodarowicz MK, Wittekind C, et al(eds):TNM Classification of Malignant Tumours(8th ed. ), John Wiley & Sons, Hoboken, 2017
3) Yang M, Moriya T, Oguma M, et al:Microinvasive ductal carcinoma(T1 mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases. Pathol Int 53:422-428, 2003
4) Tan PH, Sahin AA:Atlas of Differential Diagnosis in Breast Pathology, Springer, New York, 2017, pp292-297
5) Hoda SA, Brogi E, Koerner FC, et al(eds):Rosen's Breast Pathology(5th ed. ), Wolters Kluwer, Philadelphia, 2021, p103
6) Morita M, Yamaguchi R, Tanaka M, et al:CD8(+)tumorinfiltrating lymphocytes contribute to spontaneous"healing"in HER2-positive ductal carcinoma in situ. Cancer Med 5:1607-1618, 2016
7) Hoda SA, Brogi E, Koerner FC, et al(eds):Rosen's Breast Pathology(5th ed. ), Wolters Kluwer, Philadelphia, 2021, p416
P.84 掲載の参考文献
1) Li CI, Anderson BO, Daling JR, et al:Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 289:1421-1424, 2003
2) Li CI, Anderson BO, Porter P, et al:Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer 88:2561-2569, 2000
3) Daling JR, Malone KE, Doody DR, et al:Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95:2455-2464, 2002
4) Arpino G, Bardou VJ, Clark GM, et al:Infiltrating lobular carcinoma of the breast:tumor characteristics and clinical outcome. Breast Cancer Res 6:149-156, 2004
5) Hilleren DJ, Andersson IT, Lindholm K, et al:Invasive lobular carcinoma:mammographic findings in a 10-year experience. Radiology 178:149-154, 1991
6) Mann RM, Kuhl CK, Kinkel K, et al:Breast MRI:guidelines from the European Society of Breast Imaging. Eur Radiol 18:1307-1318, 2008
7) Winchester DJ, Chang HR, Graves TA, et al:A comparative analysis of lobular and ductal carcinoma of the breast:presentation, treatment, and outcomes. J Am Coll Surg 186:416-422, 1998
8) Nakagawa S, Miki Y, Miyashita M, et al:Tumor microenvironment in invasive lobular carcinoma:possible therapeutic targets. Breast Cancer Res Treat 155:65-75, 2016
9) Fechner RE:Histologic variants of infiltrating lobular carcinoma of the breast. Hum Pathol 6:373-378, 1975
10) Sneige N, Wang J, Baker BA, et al:Clinical, histopathologic, and biologic features of pleomorphic lobular(ductallobular)carcinoma in situ of the breast:a report of 24 cases. Mod Pathol 15:1044-1050, 2002
11) Rakha EA, van Deurzen CH, Paish EC, et al:Pleomorphic lobular carcinoma of the breast:is it a prognostically significant pathological subtype independent of histological grade? Mod Pathol 26:496-501, 2013
12) McCart Reed AE, Kutasovic JR, Nones K, et al:Mixed ductal-lobular carcinomas:evidence for progression from ductal to lobular morphology. J Pathol 244:460-468, 2018
13) De Leeuw WJ, Berx G, Vos CB, et al:Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 183:404-411, 1997
14) Oka H, Shiozaki H, Kobayashi K, et al:Expression of Ecadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 53:1696-1701, 1993
15) Da Silva L, Parry S, Reid L, et al:Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 32:773-783, 2008
16) Acs G, Lawton TJ, Rebbeck TR, et al:Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Am J Clin Pathol 115:85-98, 2001
17) Weigelt B, Geyer FC, Natrajan R, et al:The molecular underpinning of lobular histological growth pattern:a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade-and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 220:45-57, 2010
18) Corso G, Figueiredo J, La Vecchia C, et al:Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect. J Med Genet 55:431-441, 2018
19) Ciriello G, Gatza ML, Beck AH, et al:Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163:506-519, 2015
20) Desmedt C, Salgado R, Fornili M, et al:Immune infiltration in invasive lobular breast cancer. J Natl Cancer Inst 110:768-776, 2018
P.87 掲載の参考文献
1) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018
2) van Deurzen CHM, Denkert C, Purdie CA:Tubular carcinoma. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumors, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp119-120
3) Rakha EA, Lee AH, Evans AJ, et al:Tubular carcinoma of the breast:further evidence to support its excellent prognosis. J Clin Oncol 28:99-104, 2010
4) Metovic J, Bragoni A, Osella-Abate S, et al:Clinical relevance of tubular breast carcinoma:large retrospective study and meta-analysis. Front Oncol 11:653388, 2021
5) 日本乳癌学会(編):乳癌診療ガイドライン 1 治療編2018年版, 金原出版, 2018
6) Wu SG, Zhang WW, Sun JY, et al:Omission of postoperative radiotherapy in women aged 65 years or older with tubular carcinoma of the breast after breast-conserving surgery. Front Oncol 8:190, 2018
7) Brogi E:Tubular carcinoma. in Hoda SA, Brogi E, Koerner FC, et al(eds):"Rosen's Breast Pathology"(5th ed. ), Wolters Kluwer, Philadelphia, 2020, pp516-538
8) Rosen PP:Columnar cell hyperplasia is associated with lobular carcinoma in situ and tubular carcinoma. Am J Surg Pathol 23:1561, 1999
9) Collins LC, Cole KS, Marotti JD, et al:Androgen receptor expression in breast cancer in relation to molecular phenotype:results from the Nurses' Health Study. Mod Pathol 24:924-931, 2011
10) Abdel-Fatah TM, Powe DG, Hodi Z, et al:Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions:further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 32:513-523, 2008
11) Lopez-Garcia MA, Geyer FC, Natrajan R, et al:Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtypematched ductal and lobular carcinomas. J Pathol 222:64-75, 2010
P.90 掲載の参考文献
1) Van Deurzen CHM, Denkert C, Purdie CA, et al:Cribriform carcinoma. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp121-122
2) Page DL, Dixon JM, Anderson TJ, et al:Invasive cribriform carcinoma of the breast. Histopathology 7:525-536, 1983
3) Liu XY, Jiang YZ, Liu YR, et al:Clinicopathological characteristics and survival outcomes of invasive cribriform carcinoma of breast:a SER population-based study. Medicine(Baltimore) 94:e1309, 2015
4) Ng WK:Fine needle aspiration cytology of invasive cribriform carcinoma of the breast with osteoclastlike giant cells:a case report. Acta Cytol 45:593-598, 2001
5) Sinem D, Gulten S, Aysegul AS, et al:Clinicopathological analysis of invasive cribriform carcinoma of the breast, with review of the literature. Ann Diagn Pathol 54:151794, 2021
P.95 掲載の参考文献
1) Wen HY, Desmedt C, Reis-Fiho JS, et al:Mucinous carcinoma. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast tumours"(5th ed. ), IARC, Lyon, 2019:pp123-125
2) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018, pp29-30
3) Lu K, Wang X, Zhang W, et al:Clinicopathological and genomic features of breast mucinous carcinoma. Breast 53:130-137, 2020
4) Ginter PS, Tang X, Shin SJ:A review of mucinous lesions of the breast. Breast J 26:1168-1178, 2020
5) Matsuda M, Yoshimoto M, Iwase T, et al:Mammographic and clinicopathological features of mucinous carcinoma of the breast. Breast Cancer 7:65-70, 2000
6) Ranade A, Batra R, Sandhu G, et al:Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micropapillary pattern. J Clin Pathol 63:1043-1047, 2010
7) Xu X, Bi R, Shui R, et al:Micropapillary pattern in pure mucinous carcinoma of the breast-does it matter or not? Histopathology 74:248-255, 2019
8) Chaudhry AR, Khoury ME, Gotra A, et al:Imaging features of pure and mixed forms of mucinous breast carcinoma with histopathological correlation. Br J Radiol 92:20180810, 2019
9) Capella C, Eusebi V, Mann B, et al:Endocrine differentiation in mucoid carcinoma of the breast. Histopathology 4:613-630, 1980
10) Collins LC, Cole KS, Marotti JD, et al:Androgen receptor expression in breast cancer in relation to molecular phenotype:results from the nurses' health study. Mod Pathol 24:924-931, 2011
11) Domfeh AB, Carley AL, Striebel JM, et al:WT1 immunoreactivity in breast carcinoma:selective expression in pure and mixed mucinous subtypes. Mod Pathol 21:1217-1223, 2008
12) Wendroth SM, Mentrikoski MJ, Wick MR:GATA3 expression in morphologic subtypes of breast carcinoma:a comparison with gross cystic disease fluid protein 15 and mammaglobin. Ann Diagn Pathol 19:6-9, 2015
13) Pareja F, Lee JY, Brown DN, et al:The Genomic landscape of mucinous breast cancer. J Natl Cancer Inst 111:737-741, 2019
14) Pareja F, Selenica P, Brown DN, et al:Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma. Histopathology 75:139-145, 2019
15) RosenPP:Mucocele-like tumors of the breast. Am J Surg Pathol 10:464-469, 1986
16) Honma N, Sakamoto G, Ikenaga M, et al:Mucinous cystadenocarcinoma of the breast:a case report and review of the literature. Arch Pathol Lab Med 127:1031-1033, 2003
17) Coyne JD, Irion L:Mammary mucinous cystadenocarcinoma. Histopathology 49:659-660, 2006
18) Maluf HM, Koerner FC:Solid papillary carcinoma of the breast. A form of intraductal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma. Am J Surg Pathol 19:1237-1244, 1995
19) Wesseling J, van der Valk SW, Vos HL, et al:Episialin(MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129:255-265, 1995
P.100 掲載の参考文献
1) Fisher ER, Palekar AS, Redmond C, et al:Pathologic findings from the National Surgical Adjuvant Breast Project(protocol no. 4). VI. Invasive papillary cancer. Am J Clin Pathol 73:313-322, 1980
2) Siriaunkgul S, Tavassoli FA:Invasive micropapillary carcinoma of the breast. Mod Pathol 6:660-662, 1993
3) Marchio C, Horlings HM, Vincent-Salomon A:Invasive micropapillary carcinoma. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5 th ed. ), IARC, Lyon, 2019, pp128-130
4) Yang YL, Liu BB, Zhang X, et al:Invasive micropapillary carcinoma of the breast:an update. Arch Pathol Lab Med 140:799-805, 2016
5) Guo X, Chen L, Lang R, et al:Invasive micropapillary carcinoma of the breast:association of pathologic features with lymph node metastasis. Am J Clin Pathol 126:740-746, 2006
6) Ide Y, Horii R, Osako T, et al:Clinicopathological significance of invasive micropapillary carcinoma component in invasive breast carcinoma. Pathol Int 61:731-736, 2011
7) Marchio C, Iravani M, Natrajan R, et al:Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 215:398-410, 2008
8) Vingiani A, Maisonneuve P, Dell'orto P, et al:The clinical relevance of micropapillary carcinoma of the breast:a case-control study. Histopathology 63:217-224, 2013
9) Wu Y, Zhang N, Yang Q:The prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in the breast:a meta-analysis. BMC Cancer 17:839, 2017
10) Adrada B, Arribas E, Gilcrease M, et al:Invasive micropapillary carcinoma of the breast:mammographic, sonographic, and MRI features. AJR Am J Roentgenol 193:W58-63, 2009
11) Lim HS, Kuzmiak CM, Jeong SI, et al:Invasive micropapillary carcinoma of the breast:MR imaging findings. Korean J Radiol 14:551-558, 2013
12) Luna-More S, Gonzalez B, Acedo C, et al:Invasive micropapillary carcinoma of the breast. A new special type of invasive mammary carcinoma. Pathol Res Pract 190:668-674, 1994
13) Acs G, Esposito NN, Rakosy Z, et al:Invasive ductal carcinomas of the breast showing partial reversed cell polarity are associated with lymphatic tumor spread and may represent part of a spectrum of invasive micropapillary carcinoma. Am J Surg Pathol 34:1637-1646, 2010
14) Stewart RL, Caron JE, Gulbahce EH, et al:HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features. Mod Pathol 30:1561-1566, 2017
15) Weigelt B, Horlings HM, Kreike B, et al:Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 216:141-150, 2008
16) Natrajan R, Wilkerson PM, Marchio C, et al:Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol 232:553-565, 2014
17) Marchio C, Iravani M, Natrajan R, et al:Mixed micropapillary-ductal carcinomas of the breast:a genomic and immunohistochemical analysis of morphologically distinct components. J Pathol 218:301-315, 2009
18) Wesseling J, van der Valk SW, Vos HL, et al:Episialin(MUC1)overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129:255-265, 1995
19) Acs G, Dumoff KL, Solin LJ, et al:Extensive retraction artifact correlates with lymphatic invasion and nodal metastasis and predicts poor outcome in early stage breast carcinoma. Am J Surg Pathol 31:129-140, 2007
20) Wen HY, Desmedt C, Reis-Filho CS, et al:Mucinous carcinoma. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp123-125
21) Bombonati A, Lerwill MF:Metastases to and from the Breast. Surg Pathol Clin 5:719-747, 2012
P.104 掲載の参考文献
1) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018
2) Provenzano E, Gatalica Z, Vranic S:Carcinoma with apocrine differentiation. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp131-133
3) Brogi E:Apocrine carcinoma. in Hoda SA, Brogi E, Koerner FC, et al(eds):"Rosen's Breast Pathoogy"(5 th ed. ), Wolters Kluwer, Philadelphia, 2021, pp707-731
4) Vranic S, Tawfik O, Palazzo J, et al:EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 23:644-653, 2010
5) Farmer P, Bonnefoi H, Becette V, et al:Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24:4660-4671, 2005
6) Turner NC, Reis-Filho JS:Tackling the diversity of triplenegative breast cancer. Clin Cancer Res 19:6380-6388, 2013
7) Lehmann-Che J, Hamy AS, Porcher R, et al:Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res 15:R37, 2013
8) Patani N, Barbashina V, Lambros MB, et al:Direct evidence for concurrent morphological and genetic heterogeneity in an invasive ductal carcinoma of triple-negative phenotype. J Clin Pathol 64:822-828, 2011
10) Cserni G:Benign apocrine papillary lesions of the breast lalcking or virtually lacking myoepithelial cells. Potential pitfalls in diagnosing malignancy. APMIS 120:249-252, 2012
P.109 掲載の参考文献
1) Reis-Filho JS, Gobbi H, McCart Reed AE, et al:Metaplastic carcinoma. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp134-138
2) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018, pp30-31
3) Langlands F, Cornford E, Rakha E, et al:Imaging overview of metaplastic carcinomas of the breast:a large study of 71 cases. Br J Radiol 89:20140644, 2016
4) Yang WT, Hennessy B, Broglio K, et al:Imaging differences in metaplastic and invasive ductal carcinomas of the breast. AJR Am J Roentgenol 189:1288-1293, 2007
5) Cserni G, Quinn CM, Foschini MP, et al:Triple-negative breast cancer histological subtypes with a favourable prognosis. Cancers 13:5694, 2021
6) Sasaki Y, Tsuda H, Ueda S, et al:Histological differences between invasive ductal carcinoma with a large central acellular zone and matrix-producing carcinoma of the breast. Pathol Int 59:390-394, 2009
7) Voutilainen S, Heikkila P, Sampo M, et al:Expression of markers of stem cell characteristics, epithelial-mesenchymal transition, basal-like phenotype, proliferation, and androgen receptor in metaplastic breast cancer and their prognostic impact. Acta Oncol 60:1233-1239, 2021
8) McMullen ER, Zoumberos NA, Kleer CG:Metaplastic breast carcinoma:update of histopathology and molecular alterations. Arch Pathol Lab Med 143:1492-1496, 2019
9) Rakha EA, Coimbra NDM, Hodi Z, et al:Immunoprofile of metaplastic carcinomas of the breast. Hisopathology 70:975-985, 2017
10) Kawaguchi K, Shin SJ:Immunohistochemiacal staining characteristics of low-grade adenosquamous carcinoma of the breast. Am J Surg Pathol 36:1009-1020, 2012
11) Bataillon G, Fuhrmann L, Girard E, et al:High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast. Histopathology 73:273-283, 2018
14) Weigelt B, Kreike B, Reis-Filho JS:Metaplastic breast carcinomas are basal-like breast cancers:a genomic profiling analysis. Breast Cancer Res Treat 117:273-280, 2009
15) Part A, Parker JS, Karginova O, et al:Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68, 2010
16) Weigelt B, Ng CK, Shen R, et al:Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity[corrected]. Mod Pathol 28:340-351, 2015
17) Krings G, Chen YY:Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma. Mod Pathol 31:1661-1674, 2018
18) Ng CK, Piscuoglio S, Geyer FC, et al:The landscape of somatic genetic alterations in metaplastic breast carcinomas. Clin Cancer Res 23:3859-3870, 2017
19) McCart Reed AE, Kalaw E, Nones K, et al:Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications. J Pathol 247:214-227, 2019
P.112 掲載の参考文献
1) Azzopardi JG, Muretto P, Goddeeris P, et al:'Carcinoid' tumours of the breast:the morphological spectrum of argyrophil carcinomas. Histopathology 6:549-569, 1982
2) Lakhani SR, Ellis IO, Schnitt SJ, et al(eds):WHO Classification of Tumours of the Breast(4th ed. ), IARC, Lyon, 2012
3) WHO Classification of Tumours Editorial Board(ed):WHO Classification of Tumors, Breast Tumours(5th ed. ), IARC, Lyon, 2019
4) Cloyd JM, Yang RL, Allison KH, et al:Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. Breast Cancer Res Treat 148:637-644, 2014
5) Roininen N, Takala S, Haapasaari KM, et al:Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile:a retrospective clinical study. BMC Cancer 17:72, 2017
6) Kelten Talu C, Leblebici C, Kilicaslan Ozturk T, et al:Primary breast carcinomas with neuroendocrine features:clinicopathological features and analysis of tumor growth patterns in 36 cases. Ann Diagn Pathol 34:122-130, 2018
7) Lavigne M, Menet E, Tille JC, et al:Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Mod Pathol 31:68-82, 2018
8) Bogina G, Munari E, Brunelli M, et al:Neuroendocrine differentiation in breast carcinoma:clinicopathological features and outcome. Histopathology 68:422-432, 2016
9) Kwon SY, Bae YK, Gu MJ, et al:Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. Histopathology 64:647-659, 2014
10) Sapino A, Righi L, Cassoni P, et al:Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod Pathol 14:768-776, 2001
11) Pareja F, D'Alfonso TM:Neuroendocrine neoplasms of the breast:a review focused on the updated World Health Organization(WHO) 5th edition morphologic classification. Breast J 26:1160-1167, 2020
12) Marchio C, Geyer FC, Ng CK, et al:The genetic landscape of breast carcinomas with neuroendocrine differentiation. J Pathol 241:405-419, 2017
13) Shin SJ, DeLellis RA, Ying L, et al:Small cell carcinoma of the breast:a clinicopathologic and immunohistochemical study of nine patients. Am J Surg Pathol 24:1231-1238, 2000
14) McCullar B, Pandey M, Yaghmour G, et al:Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung. Breast Cancer Res Treat 158:195-202, 2016
15) Pareja F, Vahdatinia M, Marchio C, et al:Neuroendocrine tumours of the breast:a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. J Clin Pathol 75:10-17, 2022
16) Wei Y, Ke X, Yu J, et al:Clinical and genomic analyses of neuroendocrine neoplasms of the breast. Mod Pathol 35:495-505, 2022
17) Bean GR, Najjar S, Shin SJ, et al:Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast. Mod Pathol, 2022, doi:10.1038/s41379-022-01090-y. online ahead of print
P.115 掲載の参考文献
1) Pareja F, Weigelt B, Reis-Filho JS:Problematic breast tumors reassessed in light of novel molecular data. Mod Pathol 34:38-47, 2021
2) Foschini MP, Geyer FC, Marchio C, et al:Rare and salivary gland-type tumours. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp139-154
3) Cima L, Kaya H, Marchio C, et al:Triple-negative breast carcinomas of low malignant potential:review on diagnostic criteria and differential diagnoses. Virchows Arch 480:109-126, 2022
4) Tan PH, Ellis IO, Foschini MP, et al:Epithelial-myoepithelial tumours. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp39-48
5) Brogi E:Adenoid cystic carcinoma. in Hoda SA, Brogi E, Koerner FC, et al(eds):"Rosen's Breast Pathology"(5th ed. ), Wolters Kluwer, Philadelphia, 2021, pp799-827
P.119 掲載の参考文献
1) Krings G, Chen YY, Sorensen PHB, et al:Secretory carcinoma. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp146-148
2) McDivitt RW, Stewart FW:Breast carcinoma in children. JAMA 195:388-390, 1966
3) 日本乳癌学会:年次乳癌登録集計/全国乳がん患者登録調査報告(2004~2016年)
4) Osako T, Takeuchi K, Horii R, et al:Secretory carcinoma of the breast and its histopathological mimics:value of markers for differential diagnosis. Histopathology 63:509-519, 2013
5) Koerner FC:Secretory carcinoma. in Hoda SA, Brogi E, Koerner FC, et al(eds):"Rosen's Breast Pathology"(5 th ed. ), Wolters Kluwer, Philadelphia, 2021, pp762-776
6) Li D, Xiao X, Yang W, et al:Secretory breast carcinoma:a clinicopathological and immunophenotypic study of 15 cases with a review of the literature. Mod Pathol 25:567-575, 2012
7) Krings G, Joseph NM, Bean GR, et al:Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. Mod Pathol 30:1086-1099, 2017
8) Tognon C, Knezevich SR, Huntsman D, et al:Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2:367-376, 2002
9) Skalova A, Bell D, Bishop JA, et al:Secretory carcinoma. in El-Nagger AK, Chan JKC, Grandis JR, et al(eds):"WHO Classification of Head and Neck Tumours"(4th ed. ), IARC, Lyon, 2017, pp177-178
10) Dogan S, Wang L, Ptashkin RN, et al:Mammary analog secretory carcinoma of the thyroid gland:a primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. Mod Pathol 29:985-995, 2016
11) Kazakov DV, Argenyi ZB, Brenn T, et al:Secretory carcinoma. in Elder DE, Massi D, Scolyer RA, et al(eds):"WHO Classification of Skin Tumours"(4th ed. ), IARC, Lyon, 2018, pp179-180
12) Cocco E, Scaltriti M, Drilon A:NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731-747, 2018
13) Hechtman JF, Benayed R, Hyman DM, et al:Pan-TRK immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol 41:1547-1551, 2017
14) Harrison BT, Fowler E, Krings G, et al:Pan-TRK immunohistochemistry. A useful diagnostic adjunct for secretory carcinoma of the breast. Am J Sur Pathol 43:1693-1700, 2019
15) Vasudev P, Onuma K:Secretory breast carcinoma:unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. Arch Pathol Lab Med 135:1606-1610, 2011
16) Horowitz DP, Sharma CS, Connolly E, et al:Secretory carcinoma of the breast:results from the survival, epidemiology, and end results database. Breast 21:350-353, 2012
P.129 掲載の参考文献
1) Rapin V, Contesso G, Mouriesse H, et al:Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 61:2503-2510, 1988
2) Ridolfi RL, Rosen PP, Port A, et al:Medullary carcinoma of the breast:a clinicopathologic study with 10 year followup. Cancer 40:1365-1385, 1977
3) Rakha EA, Aleskandarany M, El-Sayed ME, et al:The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. Eur J Cancer 45:1780-1787, 2009
4) Martinez SR, Beal SH, Canter RJ, et al:Medullary carcinoma of the breast:a population-based perspective. Med Oncol 28:738-744, 2011
5) Pedersen L, Zedeler K, Holck S, et al:Medullary carcinoma of the breast, proposal for a new simplified histopathological definition. Based on prognostic observations and observations on inter-and intraobserver variability of 11 histopathological characteristics in 131 breast carcinomas with medullary features. Br J Cancer 63:591-595, 1991
6) Wargotz ES, Silverberg SG:Medullary carcinoma of the breast:a clinicopathologic study with appraisal of current diagnostic criteria. Hum Pathol 19:1340-1346, 1988
7) Vincent-Salomon A, Gruel N, Lucchesi C, et al:Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 9:R24, 2007
8) Romero P, Benhamo V, Deniziaut G, et al:Medullary breast carcinoma, a triple-negative breast cancer associated with BCLG overexpression. Am J Pathol 188:2378-2391, 2018
9) Krawczyk N, Rower R, Anlauf M, et al:Invasive breast carcinoma with neuroendocrine differentiation:a singlecenter analysis of clinical features and prognosis. Geburtshilfe Frauenheilkd 82:68-84, 2021
10) Holland R, van Haelst UJ:Mammary carcinoma with osteoclast-like giant cells. Additional observations on six cases. Cancer 53:1963-1973, 1984
11) Zhou S, Yu L, Zhou R, et al:Invasive breast carcinomas of no special type with osteoclast-like giant cells frequently have a luminal phenotype. Virchows Arch 464:681-688, 2014
12) Horlings HM, Weigelt B, Anderson EM, et al:Genomic profiling of histological special types of breast cancer. Breast Cancer Res Treat 142:257-269, 2013
13) Silver SA, Tavassoli FA:Pleomorphic carcinoma of the breast:clinicopathological analysis of 26 cases of an unusual high-grade phenotype of ductal carcinoma. Histopathology 36:505-514, 2000
14) Tang H, Liu F, Li H, et al:Pleomorphic carcinoma of breast:a case report and review of literature. Int J Clin Exp Pathol 7:5215-5220, 2014
15) Nguyen CV, Falcon-Escobedo R, Hunt KK, et al:Pleomorphic ductal carcinoma of the breast:predictors of decreased overall survival. Am J Surg Pathol 34:486-493, 2010
16) Zhou Z, Kinslow CJ, Hibshoosh H, et al:Clinical features, survival and prognostic factors of glycogen-rich clear cell carcinoma(GRCC) of the breast in the U. S. population. J Clin Med 8:246, 2019
17) Kuroda H, Sakamoto G, Ohnisi K, et al:Clinical and pathological features of glycogen-rich clear cell carcinoma of the breast. Breast Cancer 12:189-195, 2005
18) Kim SE, Koo JS, Jung WH:Immunophenotypes of glycogen rich clear cell carcinoma. Yonsei Med J 53:1142-1146, 2012
19) Osako T, Takeuchi K, Horii R, et al:Secretory carcinoma of the breast and its histopathological mimics:value of markers for differential diagnosis. Histopathology 63:509-519, 2013
20) Osako T:How can we better distinguish metastatic tumors from primary tumors in the breast? Expert Rev Anticancer Ther 21:913-916, 2021
21) Eusebi V, Damiani S, Ellis IO, et al:Breast tumor resembling the tall cell variant of papillary thyroid carcinoma:report of 5 cases. Am J Surg Pathol 27:1114-1118, 2003
22) Chiang S, Weigelt B, Wen HC, et al:IDH2 Mutations define a unique subtype of breast cancer with altered nuclear polarity. Cancer Res 76:7118-7129, 2016
23) Wei Y, Ding L, Song X, et al:Tall cell carcinoma with reversed polarity:case report with gene sequencing and literature review. Gland Surg 10:3147-3154, 2021
24) Foschini MP, Asioli S, Foreid S, et al:Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms:a unique invasive tumor with indolent behavior. Am J Surg Pathol 41:887-895, 2017
25) 大迫 智:乳がんにおけるgenotype-phenotype correlation. がん分子標的治療 17:101-104, 2019
26) Marotti JD, Schnitt SJ:Genotype-phenotype correlations in breast cancer. Surg Pathol Clin 11:199-211, 2018
P.136 掲載の参考文献
1) Thike AA, Brogi E, Harada O, et al:Fibroadenoma. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, pp168-171
2) Carney JA, Toorky BC:Myxoid fibroadenoma and allied conditions(myxomatosis) of the breast. A heritable disorder with special associations including cardiac and cutaneous mxyomas. Am J Surg Pathol 15:713-721, 1991
3) Brogi E:Fibroepithelial neoplasms. in Hoda SA, Brogi E, Koerner FC, et al(eds):"Rosen's Breast Pathology"(5th ed. ), Wolters Kluwer, Philadelphia, 2020, pp227-289
4) Tse G, Koo JS, Thike AA, et al:Phyllodes tumour. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours"(5th ed. ), IARC, Lyon, 2019, p174
5) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018
6) Lim WK, Ong CK, Tan J, et al:Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet 46:877-880, 2014
7) Tan J, Ong CK, Lim WK, et al:Genomic landscapses of breast fibroepithelial tumours. Nat Genet 47:1341-1345, 2015
8) Loke BN, Md Nasir ND, Thike AA, et al:Genetics and genomics of breast fibroadenomas. J Clin Pathol 71:381-387, 2018
9) Md Nasir ND, Ng CCY, Rajasegaran V, et al:Genomic characterisation of breast fibroepithelial lesions in an international cohort. J Pathol 249:447-460, 2019
10) Troxell ML, Levine J, Beadling C, et al:High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol 23:27-37, 2010
11) Volckmar AL, Leichsenring J, Flechtenmacher C, et al:Tubular, lactating, and ductal adenomas are devoid of MED12 exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway. Genes Chromosomes Cancer 56:11-17, 2017
12) Ross DS, Giri DD, Akram MM, et al:Fibroepithelial lesions in the breast of adolescent females:a clinicopathological study of 54 cases. Breast J 23:182-192, 2017
13) Yasir S, Nassar A, Jimenez RE, et al:Cellular fibroepithelial lesions of the breast:a long term follow up study. Ann Diagn Pathol 35:85-91, 2018
P.142 掲載の参考文献
1) WHO Classification of Tumours Editorial Board(ed):WHO Classification of Tumours, Breast Tumours(5th ed. ), IARC, Lyon, 2019
2) Pimiento JM, Gadgil PV, Santillan AA, et al:Phyllodes tumors:race-related differences. J Am Coll Surg 213:537-542, 2011
3) Tan PH:Fibroepithelial lesions revisited:implications for diagnosis and management. Mod Pathol 34:15-37, 2021
4) Tan BY, Acs G, Apple SK, et al:Phyllodes tumours of the breast:a consensus review. Histopathology 68:5-21, 2016
5) Tan PH, Thike AA, Tan WJ, et al:Predicting clinical behaviour of breast phyllodes tumours:a nomogram based on histological criteria and surgical margins. J Clin Pathol 65:69-76, 2012
6) 日本乳癌学会(編):乳癌診療ガイドライン1 治療編 2022年版, 金原出版, 2022
7) Toussaint A, Piaget-Rossel R, Stormacq C, et al:Width of margins in phyllodes tumors of the breast:the controversy drags on?-a systemic review and meta-analysis. Breast Cancer Res Treat 185:21-37, 2021
8) Wen B, Mousadoust D, Warburton R, et al:Phyllodes tumours of the breast:outcomes and recurrence after excision. Am J Surg 219:790-794, 2020
9) Resetkova E, Khazai L, Albarracin CT, et al:Clinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast. Breast J 16:573-580, 2010
10) Hirose M, Hashizume T, Seino N, et al:Atlas of breast magnetic resonance imaging. Curr Probl Diagn Radiol 36:51-65, 2007
11) Lerwill MF, Lee AHS, Tan PH:Fibroepithelial tumours of the breast-a review. Virchows Arch 480:45-63, 2022
12) Rakha EA, Brogi E, Castellano I, et al:Spindle cell lesions of the breast:a diagnostic approach. Virchows Arch 480:127-145, 2022
13) Lim WK, Ong CK, Tan J, et al:Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. Nat Genet 46:877-880, 2014
14) Ng CCY, Tan J, Ong CK, et al:MED12 is frequently mutated in breast phyllodes tumours:a study of 112 cases. J Clin Pathol 68:685-691, 2015
15) Sim Y, Ng GXP, Ng CCY, et al:A novel genomic panel as an adjunctive diagnostic tool for the characterization and profiling of breast fibroepithelial lesions. BMC Med Genomics 12:142, 2019
16) Md Nasir ND, Ng CCY, Rajasegaran V, et al:Genomic characterisation of breast fibroepithelial lesions in an international cohort. J Pathol 249:447-460, 2019
17) Nozad S, Sheehan CE, Gay LM, et al:Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Res Treat 162:597-602, 2017
18) Chang HY, Koh VCY, Md Nasir ND, et al:MED12, TERT and RARA in fibroepithelial tumours of the breast. J Clin Pathol 73:51-56, 2020
19) Bacchi CE, Wludarski SC, Lamovec J, et al:Lipophyllodes of the breast. A reappraisal of fat-rich tumors of the breast based on 22 cases integrated by immunohistochemical study, molecular pathology insights, and clinical follow-up. Ann Diagn Pathol 21:1-6, 2016
20) Lyle PL, Bridge JA, Simpson JF, et al:Liposarcomatous differentiation in malignant phyllodes tumours is unassociated with MDM2 or CDK4 amplification. Histopathology 68:1040-1045, 2016
P.148 掲載の参考文献
1) WHO Classification of Tumours of Editorial Board(ed):WHO Classification of Tumours, Breast Tumours(5th ed. ), IRAC, Lyon, 2019
2) 森谷卓也, 堀井理絵, 大井恭代, 他:乳癌の基礎知識. 日本乳癌学会(編):乳腺腫瘍学, 第3版, 金原出版, 2020, pp2-7, 11-41
3) Montagna W, Yun JS:The glands of Montgomery. Br J Dermatol 86:126-133, 1972
4) Elder DE, Massi D, Scolyer RA, et al(eds):WHO Classification of Skin Tumours(4th ed. ), IARC, Lyon, 2018
5) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018
6) Paget J:On disease of the mammary areola preceding cancer of the mammary gland. St Bartholomew's Hosp Rep 10:87-89, 1874
7) Sanders MA, Dominici L, Denison C, et al:Paget disease of the breast with invasion from nipple skin into the dermis:an unusual type of skin invasion not associated with an adverse outcome. Arch Pathol Lab Med 137:72-76, 2013
8) 塩見達志:病理形態学キーワード. 病理と臨床 28(臨時増刊):410-411, 2010
9) Roy M, Teshome M, Damodaran S, et al:Male mammary Paget disease:a tale of 2 contrasting cases. Am J Dermatopathol 42:981-985, 2020
11) Spohn GP, Trotter SC, Tozbikian G, et al:Nipple adenoma in a female patient presenting with persistent erythema of the right nipple skin:case report, review of the literature, clinical implications, and relevancy to health care providers who evaluate and treat patients with dermatologic conditions of the breast skin. BMC Dermatol 16:4, 2016
12) Ichinokawa Y, Ohtuki A, Hattori M, et al:A case of syringomatous adenoma of the nipple. Case Rep Dermatol 4:98-103, 2012
P.156 掲載の参考文献
1) WHO Classification of Tumours Editorial Board(ed):WHO Classification of Tumours, Breast Tumours(5th ed. ), IARC, Lyon, 2019
2) Nitsche K, Gunther B, Katenkamp D, et al:Thoracic neoplasms at the Jena reference center for soft tissue tumors. J Cancer Res Clin Oncol 138:415-424, 2012
3) Voutsadakis IA, Zaman K, Leyvraz S:Breast sarcomas:current and future perspectives. Breast 20:199-204, 2011
4) Confavreux C, Lurkin A, Mitton N, et al:Sarcomas and malignant phyllodes tumours of the breast-a retrospective study. Eur J Cancer 42:2715-2721, 2006
5) Tan PH, Ellis IO:Myoepithelial and epithelial-myoepithelial, mesenchymal and fibroepithelial breast lesions:updates from the WHO Classification of Tumours of the Breast 2012. J Clin Pathol 66:465-470, 2013
6) Porter GJ, Evans AJ, Lee AH, et al:Unusual benign breast lesions. Clin Radiol 61:562-569, 2006
7) Schickman R, Leibman AJ, Handa P, et al:Mesenchymal breast lesions. Clin Radiol 70:567-575, 2015
8) Mele M, Jensen V, Wronecki A, et al:Myofibroblastoma of the breast:case report and literature review. Int J Surg Case Rep 2:93-96, 2011
9) Howitt BE, Fletcher CD:Mammary-type myofibroblastoma:clinicopathologic characterization in a series of 143 cases. Am J Surg Pathol 40:361-367, 2016
10) Chen BJ, Marino-Enriquez A, Fletcher CD, et al:Loss of retinoblastoma protein expression in spindle cell/pleomorphic lipomas and cytogenetically related tumors:an immunohistochemical study with diagnostic implications. Am J Surg Pathol 36:1119-1128, 2012
11) Fritchie KJ, Carver P, Sun Y, et al:Solitary fibrous tumor:is there a molecular relationship with cellular angiofibroma, spindle cell lipoma, and mammary-type myofibroblastoma? Am J Clin Pathol 137:963-970, 2012
12) Rosen PP:Vascular tumors of the breast. V. Nonparenchymal hemangiomas of mammary subcutaneous tissues. Am J Surg Pathol 9:723-729, 1985
13) Rosen PP, Jozefczyk MA, Boram LH:Vascular tumors of the breast. IV. The venous hemangioma. Am J Surg Pathol 9:659-665, 1985
14) Rosen PP:Vascular tumors of the breast. III. Angiomatosis. Am J Surg Pathol 9:652-658, 1985
15) Jozefczyk MA, Rosen PP:Vascular tumors of the breast. II. Perilobular hemangiomas and hemangiomas. Am J Surg Pathol 9:491-503, 1985
16) Tilve A, Mallo R, Perez A, et al:Breast hemangiomas:correlation between imaging and pathologic findings. J Clin Ultrasound 40:512-517, 2012
17) Funamizu N, Tabei I, Sekine C, et al:Breast hemangioma with difficulty in preoperative diagnosis:a case report. World J Surg Oncol 12:313, 2014
P.159 掲載の参考文献
1) Wiseman C, Liao KT:Primary lymphoma of the breast. Cancer 29:1705-1712, 1972
2) Chan JKC:Haematolymphoid tumours of the breast, Introduction. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast tumours"(5th ed. ), IARC, Lyon, 2019, pp233-234
3) 福原傑, 飛内賢正:節外リンパ腫の臓器別特徴と治療, 乳腺リンパ腫. 日本臨牀 73(増刊号8):632-637, 2015
4) 吉野正:疾患各論:病理レポートを理解するためのポイント. リンパ腫関連疾患. 耳鼻咽喉科・頭頸部外科 93:250-255, 2021
5) Yoneyama K, Nakagawa M, Hara A:Primary lymphoma of the breast:a case report and review of the literature. Radiol Case Rep 16:55-61, 2020
6) Uenaka N, Yamamoto S, Sato S, et al:Primary breast lymphoma initially diagnosed as invasive ductal carcinoma:a case report. Clin Case Rep 9:e04189, 2021
7) 高田尚良, 谷口恒平, 高田友子, 他:乳腺原発DLBCLの分子生物学的特徴. 血液内科 74:121-125, 2017
8) Lyapichev KA, Pina-Oviedo S, Medeiros LJ, et al:A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Mod Pathol 33:367-379, 2020
9) 日本乳房オンコプラスティックサージャリー学会:http://jopbs.umin.jp/index.html, http://jopbs.umin.jp/medical/guideline/docs/BIA-ALCL4-5_20220218.pdf(2022年8月閲覧)
10) Ohishi Y, Mitsuda A, Ejima K, et al:Breast implant-associated anaplastic large-cell lymphoma:first case detected in a Japanese breast cancer patient. Breast Cancer 27:499-504, 2020
P.162 掲載の参考文献
1) Hoda SA:Benign proliferative lesions of the male breast. in Hoda SA, Brogi E, Koerner FC, et al(eds):"Rosen's Breast Pathology"(5th ed. ), Wolters Kluwer, Philadelphia, 2021, pp1057-1072
2) Tan PH, Sahin AA:Male breast lesions. in"Atlas of Differential Diagnosis in Breast Pathology", Springer, Berlin, 2017, p579
3) 国立がん研究センター:がん種別統計情報, 乳房. https://ganjoho.jp/reg_stat/statistics/stat/cancer/14_breast.html(2022年9月閲覧)
4) Basham VM, Lipscombe JM, Ward JM, et al:BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 4:R2, 2002
5) Elmi M, Sequeira S, Azin A, et al:Evolving surgical treatment decisions for male breast cancer:an analysis of the National Surgical Quality Improvement Program(NSQIP)database. Breast Cancer Res Treat 171:427-434, 2018
6) Ruddy KJ, Winer EP:Male breast cancer:risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 24:1434-1443, 2013
7) Abdelwahab Yousef AJ:Male breast cancer:epidemiology and risk factors. Semin Oncol 44:267-272, 2017
8) Meijers-Heijboer H, van den Ouweland A, Klijn J, et al:Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59, 2002
9) Gurel B, Ali TZ, Montgomery EA, et al:NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 34:1097-1105, 2010
P.169 掲載の参考文献
1) Mahmoud W, El Ansari W, Hassan S, et al:Giant mammary hamartoma in a middle aged female. Case report and review of literature of the last 15 years. Int J Surg Case Rep 78:145-150, 2021
2) Tazeoglu D, Dag A, Arslan B, et al:Breast Hamartoma:clinical, radiological, and histopathological evaluation. Eur J Breast Health 17:328-332, 2021
3) Sevim Y, Kocaay AF, Eker T, et al:Breast hamartoma:a clinicopathologic analysis of 27 cases and a literature review. Clinics(Sao Paulo) 69:515-523, 2014
4) Pereira MA, de Magalhaes AV, da Motta LD, et al:Fibrous mastopathy:clinical, imaging, and histopathologic findings of 31 cases. J Obstet Gynaecol Res 36:326-335, 2010
5) Chan CL, Ho RS, Shek TW, et al:Diabetic mastopathy. Breast J 19:533-538, 2013
6) Valdez R, Thorson J, Finn WG, et al:Lymphocytic mastitis and diabetic mastopathy:a molecular, immunophenotypic, and clinicopathologic evaluation of 11 cases. Mod Pathol 16:223-238, 2003
7) Ashton MA, Lefkowitz M, Tavassoli FA:Epithelioid stromal cells in lymphocytic mastitis--a source of confusion with invasive carcinoma. Mod Pathol 7:49-54, 1994
8) Barreto DS, Sedgwick EL, Nagi CS, et al:Granulomatous mastitis:etiology, imaging, pathology, treatment, and clinical findings. Breast Cancer Res Treat 171:527-534, 2018
9) Johnstone KJ, Robson J, Cherian SG, et al:Cystic neutrophilic granulomatous mastitis associated with Corynebacterium including Corynebacterium kroppenstedtii. Pathology 49:405-412, 2017
10) Troxell ML, Gordon NT, Doggett JS, et al:Cystic neutrophilic granulomatous mastitis:association with Grampositive bacilli and Corynebacterium. Am J Clin Pathol 145:635-645, 2016
11) Yukawa M, Watatani M, Isono S, et al:Management of granulomatous mastitis:a series of 13 patients who were evaluated for treatment without corticosteroids. Int Surg 100:774-782, 2015
12) Jiang L, Li X, Sun B, et al:Clinicopathological features of granulomatous lobular mastitis and mammary duct ectasia. Oncol Lett 19:840-848, 2020
13) Dixon JM, Ravisekar O, Chetty U, et al:Periductal mastitis and duct ectasia:different conditions with different aetiologies. Br J Surg 83:820-822, 1996
14) Kenney RD, Flippo JL, Black EB:Supernumerary nipples and renal anomalies in neonates. Am J Dis Child 141:987-988, 1987
15) Ferrara P, Giorgio V, Vitelli O, et al:Polythelia:still a marker of urinary tract anomalies in children? Scand J Urol Nephrol 43:47-50, 2009
P.175 掲載の参考文献
1) Harada Y, Kubo M, Kai M, et al:Breast metastasis from pelvic high-grade serous adenocarcinoma:a report of two cases. Surg Case Rep 6:317, 2020
2) Dong F, Xie X, Wei X, et al:Metastatic serous borderline tumor with micro-invasive ovarian carcinoma presenting as a breast lump:a case report. Medicine(Baltimore) 99:e19383, 2020
3) Lee MI, Jung YJ, Kim DI, et al:Metastasis to breast from ovarian cancer and primary ovarian cancer concurrently diagnosis. Gland Surg 10:1806-1811, 2021
4) Maeshima Y, Osako T, Morizono H, et al:Metastatic ovarian cancer spreading into mammary ducts mimicking an in situ component of primary breast cancer:a case report. J Med Case Rep 15:78, 2021
5) Shah VI, Morgan SE, Kobel M, et al:Dedifferentiation in breast metastasis of endometrial carcinoma:a diagnostic dilemma. Int J Gynecol Pathol 41:35-39, 2021
6) Wang Z, Zhao D, Liu R, et al:Ovarian cancer metastasis to the breast 18 years after the initial diagnosis:a case report. Medicine(Baltimore)98:e17577, 2019
7) Kridis WB, Sghaier S, Charfi S, et al:Ovarian cancer and breast metastases:a diagnostic dilemma. Arch Iran Med 23:53-55, 2020
8) Kazakou P, Simeakis G, Alevizaki M, et al:Medullary thyroid carcinoma(MTC):unusual metastatic sites. Endocrinol Diabetes Metab Case Rep 2021:21-0063, 2021
9) Omi Y, Kamio H, Yoshida Y, et al:Breast metastasis from medullary thyroid carcinoma:a report of a case. Surg Case Rep 7:188, 2021
10) Economopoulou P, Chrysikopoulou A, Goula K, et al:Breast metastasis from neuroendocrine carcinoma of the lung:a case report and review of the literature. Case Rep Oncol 13:1281-1284, 2020
11) Verma V, Israrahmed A, Rao RN:Metastatic clear cell renal cell carcinoma presenting as breast lump:a rare case report. Diagn Cytopathol 49:E281-E285, 2021
12) Lievore E, Runza L, Ghidini M, et al:Micropapillary bladder cancer metastatic to the breast:a case report and brief literature review. In Vivo 35:453-459, 2021
13) Sahoo B Sr, Barik S, Mishra P, et al:Metastasis to breast from carcinoma gallbladder:a case report and review of literature. Cureus 12:e11307, 2020
14) Albasri AM:Nasopharyngeal carcinoma metastasis to the breast. Saudi Med J 41:1130-1134, 2020
15) Smith BM, Azouz V, Liu L, et al:Parotid adenocarcinoma metastasis to the breast:a case report. J Surg Case Rep 6:1-3, 2020
16) Jain A, Vijayakumar C, Kumbhar U, et al:Metastatic malignant melanoma mimicking mammary mass:a rare presentation. Cureus 12:e8354, 2020
17) Korsa L, Lukac A, Kovacevic L, et al:Breast metastasis as the initial presentation of malignant pleural mesothelioma. Breast J 26:2063-2064, 2020
18) Salivay C, Fadare O:High-grade endometrioid carcinoma of the endometrium with a GATA-3-positive/PAX8-negative immunophenotype metastatic to the breast:a potential diagnostic pitfall. Int J Surg Pathol 28:631-636, 2020
19) Liang MM, Teo SY, Gudi M, et al:Breast microcalcifications as the only imaging manifestation of metastatic serous peritoneal adenocarcinoma in the breast. J Radiol Case Rep 13:1-10, 2019
20) Lima V, Martinez-Lapus FG, Demegillo KJ:Breast metastasis from castrate-resistant prostatic adenocarcinoma mimicking as a second primary:a case report. World J Oncol 11:37-40, 2020
21) Devi CA, Stephen SN, Gochhait D, et al:Medullary carcinoma of thyroid metastasis to breast:a cytological experience. Diagn Cytopathol 48:169-173, 2020
22) Hasegawa H, Nagata Y, Sakakibara Y, et al:Breast metastasis from rectal cancer with BRAF V600E mutation:a case report with a review of the literature. Clin J Gastroenterol 13:153-157, 2020
23) Alzuhair AM, Gong G, Shin HJ, et al:Salivary duct cancer metastasis mimicking primary breast cancer:a case report and review. J Breast Cancer 22:653-660, 2019
24) Hsieh TC, Hsu CW:Breast metastasis from colorectal cancer treated by multimodal therapy:case report and literature review. Medicine(Baltimore)98:e18016, 2019
25) Malek D, Buccheri S, Dey CB, et al:Lung cancer metastasis to the breast mimicking inflammatory breast carcinoma on imaging. Radiol Case Rep 14:1500-1505, 2019
26) McEachron J, Mendoza R, Lee YC, et al:Breast metastases:a rare manifestation of advanced uterine serous carcinoma. Gynecol Oncol Rep 30:100500, 2019
27) Silva M, Coelho R, Rios E, et al:Breast metastasis from a combined hepatocellular-cholangiocarcinoma. ACG Case Rep J 6:e00057, 2019
28) Tripathy S, Naswa N, Jha P, et al:Ileal neuroendocrine tumor with bilateral breast and ovarian metastases:findings on 68Ga-DOTANOC PET/CT scan. Clin Nucl Med 44:e532-e534, 2019
29) Galili Y, Lytle M, Bartolomei J, et al:Clear-cell carcinoma of the ovary with bilateral breast metastases. Case Rep Oncol Med 2019:8013913, 2019
30) Papalampros A, Mpaili E, Moris D, et al:A case report on metastatic ileal neuroendocrine neoplasm to the breast masquerading as primary breast cancer:a diagnostic challenge and management dilemma. Medicine(Baltimore)98:e14989, 2019
31) Asano Y, Kashiwagi S, Takada K, et al:Alveolar soft part sarcoma metastatic to the breast:a case report. BMC Surg 19:30, 2019
32) Meng K, Chen W, Tian W, et al:Medullary thyroid carcinoma with breast metastasis:two case reports. Medicine(Baltimore)97:e13193, 2018
33) Lucchetti J, Formica V, Giuliano G, et al:Case report of a patient with breast metastasis from gastric cancer treated with paclitaxel and ramucirumab plus regional hyperthermia. Anticancer Res 38:6561-6564, 2018
34) Asaad A, Abdalla SA, Idaewor P, et al:Breast metastasis as a presentation of malignant melanoma. Chirurgia(Bucur)113:712-718, 2018
35) Deng YW, Li YW, Hao WJ, et al:A clinical observation of thymic epithelial tumor metastatic to breast. Breast Care(Basel)13:136-139, 2018
36) Tanwar P, Gandhi JS, Sharma A, et al:Unusual metastasis of medullary thyroid carcinoma to the breast:a cytological and histopathological correlation. J Cytol 35:117-120, 2018
37) Kwak BS:Metastatic small cell carcinoma of the breast from cancer of the uterine cervix:a case report. Case Rep Oncol 11:38-42, 2018
38) Kubo H, Shimizu T, Sekido H, et al:Isolated breast metastasis from gastric cancer in a male patient. Clin J Gastroenterol 11:138-144, 2018
39) Panse G, Bossuyt V, Ko CJ:Metastatic serous carcinoma presenting as inflammatory carcinoma over the breast-report of two cases and literature review. J Cutan Pathol 45:234-239, 2018
40) Ahmad SS, Khalilullah K, McGowan K, et al:Unexpected destination! Rectal carcinoma metastasis to the beast. J Surg Case Rep 2019:1-6, 2019
41) Osako T:How can we better distinguish metastatic tumors from primary tumors in the breast? Expert Rev Anticancer Ther 21:913-916, 2021
42) Raj SD, Shurafa M, Shah Z, et al:Primary and secondary breast lymphoma:clinical, pathologic, and multimodality imaging review. Radiographics 39:610-625, 2019
43) Ma Y, Liu W, Li J, et al:Gastric cancer with breast metastasis:clinical features and prognostic factors. Oncol Lett 16:5565-5574, 2018
44) Ali RH, Taraboanta C, Mohammad T, et al:Metastatic non-small cell lung carcinoma a mimic of primary breast carcinoma-case series and literature review. Virchows Arch 472:771-777, 2018
45) Hoda SA:Metastases in the breast from nonmammary neoplasms. in Hoda SA, Brogi E, Koerner FC, et al(eds):"Rosen's Breast Pathology"(4th ed. ), Wolters Kluwer, Philadelphia, 2014, pp 937-955
46) Kulka J, Varga Z:Metastases to the breast. in WHO Classification of Tumours Editorial Board(ed):"WHO Classification of Tumours, Breast Tumours(5th ed. ), IARC, Lyon, 2019, pp 262-265
P.192 掲載の参考文献
1) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018
2) WHO Classification of Tumours Editorial Board(ed):WHO Classification of Tumours, Breast Tumours(5th ed. ), IARC, Lyon, 2019
3) Saremian J, Rosa M:Solid papillary carcinoma of the breast:a pathologically and clinically distinct breast tu-mor. Arch Pathol Lab Med 136:1308-1311, 2012
4) Hoda SA, Brogi E, Koerner FC, et al(eds):Rosen's Breast Pathology(4th ed. ), Wolters Kluwer, Philadelphia, 2014, pp95-152
5) Thike AA, Iqbal J, Cheok PY, et al:Ductal carcinoma in situ associated with triple negative invasive breast cancer:evidence for a precursor-product relationship. J Clin Pathol 66:665-670, 2013
6) Lefkowitz M, Lefkowitz W, Wargotz ES:Intraductal(intracystic)papillary carcinoma of the breast and its variants:a clinicopathological study of 77 cases. Hum Pathol 25:802-809, 1994
7) Ni YB, Tse GM:Pathological criteria and practical issues in papillary lesions of the breast-a review. Histopathology 68:22-32, 2016
8) Rasbridge SA, Millis RR:Carcinoma in situ involving sclerosing adenosis:a mimic of invasive breast carcinoma. Histopathology 27:269-273, 1995
9) Lakhani SR, Ellis IO, Schnitt SJ, et al(eds):WHO Classification of Tumours of the Breast(4th ed. ), IARC, Lyon, 2012
10) Aulmann S, Braun L, Mietzsch F, et al:Transitions between flat epithelial atypia and low-grade ductal carcinoma in situ of the breast. Am J Surg Pathol 36:1247-1252, 2012
11) Collins LC:Precursor lesions of the low-grade breast neoplasia pathway. Surg Pathol Clin 11:177-197, 2018
12) Dialani V, Venkataraman S, Frieling G, et al:Does isolated flat epithelial atypia on vacuum-assisted breast core biopsy require surgical excision? Breast J 20:606-614, 2014
13) Quinn CM, D'Arcy C, Wells C:Apocrine lesions of the breast. Virchows Arch 480:177-189, 2022
14) Moriya T, Kozuka Y, Kanomata N, et al:The role of immunohistochemistry in the differential diagnosis of breast lesions. Pathology 41:68-76, 2009
15) Asirvatham JR, Falcone MM, Kleer CG:Atypical apocrine adenosis:diagnostic challenges and pitfalls. Arch Pathol Lab Med 140:1045-1051, 2016
16) Diaz NM, Palmer JO, McDivitt RW:Carcinoma arising within fibroadenomas of the breast. A clinicopathologic study of 105 patients. Am J Clin Pathol 95:614-622, 1991
17) Shiino S, Yoshida M, Tokura M, et al:Locally advanced triple negative breast cancer arising from fibroadenoma with complete response to neoadjuvant chemotherapy:a case report. Int J Surg Case Rep 68:234-238, 2020
18) Widya RL, Rodrigues MF, Truong PT, et al:Malignant epithelial transformation in phyllodes tumor:a populationbased case series. Cureus 9:e1815, 2017
19) Ohi Y, Umekita Y, Rai Y, et al:Mucocele-like lesions of the breast:a long-term follow-up study. Diagn Pathol 6:29, 2011
20) Rakha EA, Shaaban AM, Haider SA, et al:Outcome of pure mucocele-like lesions diagnosed on breast core biopsy. Histopathology 62:894-898, 2013
21) Sutton B, Davion S, Feldman M, et al:Mucocele-like lesions diagnosed on breast core biopsy. Am J Clin Pathol 138:783-788, 2012
22) Towne WS, Michaels AY, Ginter PS:Mucocele-like lesion of the breast diagnosed on core biopsy. Arch Pathol Lab Med 146:213-219, 2022
P.203 掲載の参考文献
1) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018, pp83-86
2) 大井恭代:針生検. 病理と臨床 36:952-959, 2018
3) Mooney KL, Bassett LW, Apple SK:Upgrade rates of high-risk breast lesions diagnosed on core needle biopsy:a single-institution experience and literature review. Mod Pathol 29:1471-1484, 2016
4) Harada O, Hoe R, Lin J, et al:Intranuclear inclusions in epithelial cells of benign proliferative breast lesions. J Clin Pathol 64:776-780, 2011
5) Brennan ME, Turner RM, Ciatto S, et al:Ductal carcinoma in situ at core-needle biopsy:meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 260:119-128, 2011
6) Virnig BA, Tuttle TM, Shamliyan T, et al:Ductal carcinoma in situ of the breast:a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 102:170-178, 2010
7) Koerner FC:Papilloma and related benign lesions. in Hoda SA, Brogi E, Koerner FC, et al(eds):"Rosen's Breast Pathology"(4th ed. ), Wolters Kluwer, Philadelphia, 2014, pp110-119
8) Kuba MG, Murray MP, Coffey K, et al:Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy:clinicopathologic features and findings at followup excision. Mod Pathol 34:1495-1506, 2021
9) Rosa G, Dawson A, Rowe JJ:Does identifying whether pseudoangiomatous stromal hyperplasia(PASH) is focal or diffuse on core biopsy correlate with a PASH nodule on excision? Int J Surg Pathol 25:292-297, 2017
10) Wu JM, Turashvili G:Cystic neutrophilic granulomatous mastitis:an update. J Clin Pathol 73:445-453, 2020
P.218 掲載の参考文献
1) Hilson JB, Schnitt SJ, Collins LC:Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells:biologic and diagnostic implications. Am J Surg Pathol 33:227-232, 2009
2) Hilson JB, Schnitt SJ, Collins LC:Phenotypic alterations in myoepithelial cells associated with benign sclerosing lesions of the breast. Am J Surg Pathol 34:896-900, 2010
3) Rohilla M, Bal A, Singh G, et al:Phenotypic and functional characterization of ductal carcinoma in situ-associated myoepithelial cells. Clin Breast Cancer 15:335-342, 2015
4) Cserni G:Lack of myoepithelium in apocrine glands of the breast does not necessarily imply malignancy. Histopathology 52:253-255, 2008
5) Tramm T, Kim JY, Tavassoli FA:Diminished number or complete loss of myoepithelial cells associated with meta-plastic and neoplastic apocrine lesions of the breast. Am J Surg Pathol 35:202-211, 2011
6) Bocker W, Bier B, Freytag G, et al:An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin, part I:normal breast and benign proliferative lesions. Virchows Arch A Pathol Anat Histopathol 421:315-322, 1992
7) Bocker W, Bier B, Freytag G, et al:An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV, and laminin. Part II:epitheliosis and ductal carcinoma in situ. Virchows Arch A Pathol Anat Histopathol 421:323-330, 1992
8) Leong FJ, Leong AS, Brady M, et al:Basal lamina visualization using color image processing and pattern recognition. Appl Immunohistochem Mol Morphol 13:273-276, 2005
9) Raymond WA, Leong AS:Assessment of invasion in breast lesions using antibodies to basement membrane components and myoepithelial cells. Pathology 23:291-297, 1991
P.226 掲載の参考文献
1) WHO Classification of Tumours Editorial Board(ed):WHO Classification of Tumours, Breast Tumours(5th ed. ), IARC, Lyon, 2019
2) 日本遺伝性乳癌卵巣癌総合診療制度機構(編):遺伝性乳癌卵巣癌(HBOC)診療ガイドライン, 2021年版, 金原出版, 2021
3) Daly MB, Pal T, Berry MP, et al:Genetic/familial highrisk assessment:breast, ovarian, and pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19:77-102, 2021
4) Li FP, Fraumeni JF Jr, Mulvihill JJ, et al:A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5362, 1988
5) Bougeard G, Renaux-Petel M, Flaman JM, et al:Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol 33:2345-2352, 2015
6) National Comprehensive Cancer Network:NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines(R)), Genetic/Familial High-Risk Assessment:Breast, Ovarian, and Pancreatic, Version 2, 2022. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.(2022年8月閲覧)
7) Zhang X, Chiang HC, Wang Y, et al:Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis. Nat Commun 8:15908, 2017
9) Yoshida R, Watanabe C, Yokoyama S, et al:Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutation BRCA1 L63X. Oncotarget 10:3276-3284, 2019
10) National Comprehensive Cancer Network:NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines(R)), Genetic/Familial High-Risk Assessment:Breast, Ovarian, and Pancreatic. Ver.2. 2021, 2020.
11) 小児期に発症する遺伝性腫瘍に対するがんゲノム医療体制実装のための研究:リー・フラウメニ症候群の診療ガイドライン, 2019年度版, ver.1.1. https://mhlw-grants.niph.go.jp/system/files/2019/192021/201908002B_upload/201908002B0007.pdf(2022年8月閲覧)
12) Bouaoun L, Sonkin D, Ardin M, et al:TP53 variations in human cancers:new lessons from the IARC TP53 database and genomics data. Hum Mutat 37:865-876, 2016
13) National Cancer Institute:TP53 Database. https://tp53.isb-cgc.org/(2022年8月閲覧)
14) Masciari S, Dillon DA, Rath M, et al:Breast cancer phenotype in women with TP53 germline mutations:a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 133:1125-1130, 2012
15) Limacher JM, Frebourg T, Natarajan-Ame S, et al:Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 96:238-242, 2001
16) Heymann S, Delaloge S, Rahal A, et al:Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 5:104, 2010
17) Kratz CP, Achatz MI, Brugieres L, et al:Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res 23:e38-e45, 2017
18) Lee YR, Chen M, Pandolfi PP:The functions and regulation of the PTEN tumour suppressor:new modes and prospects. Nat Rev Mol Cell Biol 19:547-562, 2018
19) 高山哲治, 五十嵐正広, 大住省三, 他:小児・成人のためのCowden 症候群/PTEN 過誤腫症候群診療ガイドライン(2020年版). 遺伝性腫瘍 20:93-114, 2020
20) Banneau G, Guedj M, MacGrogan G, et al:Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res 12:R63, 2010
21) Hermsen BB, von Mensdorff-Pouilly S, Fabry HF, et al:Lobulitis is a frequent finding in prophylactically removed breast tissue from women at hereditary high risk of breast cancer. J Pathol 206:220-223, 2005
22) Isern AE, Loman N, Malina J, et al:Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer. Eur J Surg Oncol 34:1148-1154, 2008
23) Kaas R, Verhoef S, Wesseling J, et al:Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers:very low risk for subsequent breast cancer. Ann Surg 251:488-492, 2010
24) Yamauchi H, Okawa M, Yokoyama S, et al:High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound:findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan. Breast Cancer Res Treat 172:679-687, 2018
25) 日本乳癌学会:遺伝性乳がん卵巣がん症候群の保険診療に関する手引き. http://jbcs.gr.jp/member/wp-content/uploads/2016/06/bcde8174b665e011063d9f97a22cd19c.pdf(2022年8月閲覧)
P.230 掲載の参考文献
1) Bloom HJG, Richardson WW:Histological grading and prognosis in breast cancer;a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359-377, 1957
2) Freedman LS, Edwards DN, McConnell EM, et al:Histological grade and other prognostic factors in relation to survival of patients with breast cancer. Br J Cancer 40:44-55, 1979
4) Cutler SJ, Black MM, Friedell GH, et al:Prognostic factors in cancer of the female breast. II. Reproducibility of histopathologic classification. Cancer 19:75-82, 1966
5) Le Doussal V, Tubiana-Hulin M, Friedman S, et al:Prognostic value of histologic grade nuclear components of Scar f f-Bloom-Richardson(SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 64:1914-1921, 1989
6) Tsuda H, Akiyama F, Kurosumi M, et al:Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer(NSAS-BC)Pathology Section. Jpn J Clin Oncol 28:486-491, 1998
7) Bult P, Manders P, Straatman HM, et al:In primary breast cancer the mitotic activity yields similar prognostic information as the histological grade:a study with long-term follow-up. Breast Cancer Res Treat 122:77-86, 2010
8) Ono M, Tsuda H, Yunokawa M, et al:Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptorpositive, HER2-negative, node-negative invasive breast cancers. Breast Cancer 22:141-152, 2015
9) Schwartz AM, Henson DE, Chen D, et al:Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size:a study of 161708 cases of breast cancer from the SEER Program. Arch Pathol Lab Med 138:1048-1052, 2014
10) Consensus Conference on the classification of ductal carcinoma in situ.The Consensus Conference Committee. Cancer 80:1798-1802, 1997
11) Silverstein MJ, Lagios MD:Choosing treatment for patients with ductal carcinoma in situ:fine tuning the University of Southern California/Van Nuys prognostis index. J Natl Cancer Inst Monogr 2010:193-196, 2010
P.238 掲載の参考文献
3) Goldhirsch A, Winer EP, Coates AS, et al:Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206-2223, 2013
4) Coates AS, Winer EP, Goldhirsch A, et al:Tailoring therapies--improving the management of early breast cancer:St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26:1533-1546, 2015
5) Curigliano G, Burstein HJ, Winer EP, et al:De-escalating and escalating treatments for early-stage breast cancer:the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 28:1700-1712, 2017
6) Burstein HJ, Curigliano G, Thurlimann B, et al:Customizing local and systemic therapies for women with early breast cancer:the St. Gallen International Consensus Guidelines for Treatment of Early Breast Cancer 2021. Ann Oncol 32:1216-1235, 2021
8) Early Breast Cancer Trialists' Collaborative Group(EBCTCG), Davies C, Godwin J, et al:Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials. Lancet 378:771-784, 2011
9) Prat A, Cheang MC, Martin M, et al:Prognostic significanceof progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol 31:203-209, 2013
10) DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al:Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol 37:1629-1637, 2019
11) Allison KH, Hammond MEH, Dowsett M, et al:Estrogen and progesterone receptor testing in breast cancer:ASCO/CAP guideline update. J Clin Oncol 38:1346-1366, 2020
12) Liedtke C, Broglio K, Moulder S, et al:Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20:1953-1958, 2009
13) WHO classification of tumours Editorial Board(ed):WHO Classification of Tumours, Breast Tumours(5th ed. ), IARC, Lyon, 2019
15) Dowsett M, Allred C, Knox J, et al:Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2(HER-2)status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol 26:1059-1065, 2008
18) Niikura N, Liu J, Hayashi N, et al:Loss of human epidermal growth factor receptor 2(HER2)expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30:593-599, 2012
19) Wolff AC, Hammond MEH, Allison KH, et al:Human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 36:2105-2122, 2018
20) Press MF, Sauter G, Buyse M, et al:HER2 gene amplification testing by fluorescent in situ hybridization(FISH):comparison of the ASCO-College of American Pathologists guidelines with FISH scores used for enrollment in breast cancer international research group clinical trials. J Clin Oncol 34:3518-3528, 2016
21) Petrelli F, Viale G, Cabiddu M, et al:Prognostic value of different cut-off levels of ki-67 in breast cancer:a systematic review and meta-analysis of 64, 196 patients. Breast Cancer Res Treat 153:477-491, 2015
22) Harris LN, Ismaila N, McShane LM, et al:Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer:American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34:1134-1150, 2016
23) Dowsett M, Nielsen TO, A'Hern R, et al:Assessment of Ki67 in breast cancer:recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103:1656-1664, 2011
24) Nielsen TO, Leung SCY, Rimm DL, et al:Assessment of Ki67 in breast cancer:updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 113:808-819, 2021
25) Stanton SE, Adams S, Disis ML:Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes:a systematic review. JAMA Oncol 2:1354-1360, 2016
26) Loi S, Drubay D, Adams S, et al:Tumor-infiltrating lymphocytes and prognosis:a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol 37:559-569, 2019
27) Luen SJ, Salgado R, Fox S, et al:Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel:a retrospective analysis of the CLEOPATRA study. Lancet Oncol 18:52-62, 2017
28) Adams S, Gray RJ, Demaria S, et al:Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials:ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959-2966, 2014
29) Schmid P, Adams S, Rugo HS, et al:Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108-2121, 2018
30) Cortes J, Cescon DW, Rugo HS, et al:Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer(KEYNOTE-355):a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396:1817-1828, 2020
31) Miles D, Gligorov J, Andre F, et al:Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol 32:994-1004, 2021
P.245 掲載の参考文献
1) 国立がん研究センター:がん統計. https://ganjoho.jp/reg_stat/index.html(2022年9月閲覧)
2) Visvanathan K, Hurley P, Bantug E, et al:Use of pharmacologic inter ventions for breast cancer risk reduction:American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31:2942-2962, 2013
3) Welch HG, Prorok PC, O'Malley AJ, et al:Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N Engl J Med 375:1438-1447, 2016
4) 日本乳癌学会(編):臨床・病理乳癌取扱い規約, 第18版, 金原出版, 2018, pp24-109
5) Silverstein MJ, Lagios MD, Craig PH, et al:A prognostic index for ductal carcinoma in situ of the breast. Cancer 77:2267-2274, 1996
6) Buchholz TA, Somerfield MR, Griggs JJ, et al:Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer:American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol 32:1502-1506, 2014
7) Gujam FJ, Going JJ, Mohammed ZM, et al:Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer. BMC Cancer 14:676, 2014
8) Korde LA, Somerfield MR, Carey LA, et al:Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer:ASCO guideline. J Clin Oncol 39:1485-1505, 2021
9) Allison KH:Prognostic and predictive parameters in breast pathology:a pathologist's primer. Mod Pathol 34:94-106, 2021
10) Giordano SH, Temin S, Chandarlapaty S, et al:Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer:ASCO clinical practice guideline update. J Clin Oncol 36:2736-2740, 2018
11) Paik S, Shak S, Tang G, et al:A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
12) Sparano JA, Gray RJ, Makower DF, et al:Prospective validation of a 21-gene expression assay in breast Cancer. N Engl J Med 373:2005-2014, 2015
13) van de Vijver MJ, He YD, van't Veer LJ, et al:A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
14) Naoi Y, Noguchi S:Multi-gene classifiers for prediction of recurrence in breast cancer patients. Breast Cancer 23:12-18, 2016
15) Burstein HJ, Curigliano G, Thurlimann B, et al:Customizing local and systemic therapies for women with early breast cancer:the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 32:1216-1235, 2021
16) Krop I, Ismaila N, Andre F, et al:Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer:American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol 35:2838-2847, 2017
17) Wolff AC, Hammond MEH, Allison KH, et al:Human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 36:2105-2122, 2018
18) Sparano JA, Gray RJ, Ravdin PM, et al:Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 380:2395-2405, 2019
19) Albain KS, Barlow WE, Shak S, et al:Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptorpositive breast cancer on chemotherapy:a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65, 2010
20) Cardoso F, van't Veer LJ, Bogaerts J, et al:70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:717-729, 2016
21) Park YH, Lal S, Lee JE, et al:Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome. Nat Commun 11:6175, 2020
22) Van Poznak C, Somerfield MR, Bast RC, et al:Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer:American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 33:2695-2704, 2015
23) Rossi G, Mu Z, Rademaker AW, et al:Cell-free DNA and circulating tumor cells:comprehensive liquid biopsy analysis in advanced breast cancer. Clin Cancer Res 24:560-568, 2018
24) Luchini C, Pea A, Scarpa A:Artificial intelligence in oncology:current applications and future perspectives. Br J Cancer 126:4-9, 2022
P.253 掲載の参考文献
1) Brierley JD, Gospodarowicz MK, Wittekind C(eds):TNM Classification of Malignant Tumours(8th ed. ), John Wiley & Sons, Hoboken, 2017
2) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018
3) 日本乳癌学会(編):病理診断, BQ6 乳房温存手術の病理組織学的断端診断はどのように行うか? 乳癌診療ガイドライン2 疫学・診断編2018年版, 金原出版, 2018, pp269-272
4) Osako T, Nishimura R, Nishiyama Y, et al:Efficacy of intraoperative entire-circumferential frozen section analysis of lumpectomy margins during breast-conserving surgery for breast cancer. Int J Clin Oncol 20:1093-1101, 2015
5) Cheng L, Al-Kaisi NK, Liu AY, et al:The results of intraoperative consultations in 181 ductal carcinomas in situ of the breast. Cancer 80:75-79, 1997
6) Ichihara S, Suzuki H, Kasami M, et al:A new method of margin evaluation in breast conservation surgery using an adjustable mould during fixation. Histopathology 39:85-92, 2001
7) Moran MS, Schnitt SJ, Giuliano AE, et al:Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 32:1507-1515, 2014
8) Jobsen JJ, Van Der Palen J, Ong F, et al:Differences in outcome for positive margins in a large cohort of breast cancer patients treated with breast-conserving therapy. Acta Oncol 46:172-180, 2007
9) Morrow M, Van Zee KJ, Solin LJ, et al:Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on margins for breast-conserving surgery with wholebreast irradiation in ductal carcinoma in situ. Pract Radiat Oncol 6:287-295, 2016
10) 森谷卓也:乳腺. 深山正久, 森永正二郎(編集主幹):外科病理学 II, 第5版, 文光堂, 2020, pp1219-1263
11) College of American Pathologists:Protocol for the examination of resection specimens from patients with invasive carcinoma of the breast. version:4.5.0.0, protocol posting date:June 2021. https://documents.cap.org/protocols/Breast.Invasive_4.5.0.0.REL_CAPCP.pdf(2022年9月閲覧)
12) Rea D, Francis A, Hanby AM, et al:Inflammatory breast cancer:time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Br J Cancer 112:1613-1615, 2015
13) Rakha EA, Martin S, Lee AH, et al:The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer 118:3670-3680, 2012
14) Rakha EA, Abbas A, Pinto Ahumada P, et al:Diagnostic concordance of reporting lymphovascular invasion in breast cancer. J Clin Pathol 71:802-805, 2018
15) 日本乳癌学会(編):病理診断, BQ7 センチネルリンパ節の病理学的検索はどのように行うか? 乳癌診療ガイドライン2 疫学・診断編2018年版, 金原出版, 2018, pp273-274
16) Hortobagyi GN, Connolly JL, D'Orsi CJ, et al:Breast. in Amin MB, Edge SB, Greene FL, et al(eds):"AJCC Cancer Staging Manual"(8th ed. ), Springer, Berlin, 2017, pp589-628
17) Krag DN, Anderson SJ, Julian TB, et al:Sentinel-lymphnode resection compared with conventional axillarylymph-node dissection in clinically node-negative patients with breast cancer:overall sur vival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927-933, 2010
19) Tsujimoto M, Nakabayashi K, Yoshidome K, et al:Onestep nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 13:4807-4816, 2007
20) Maguire A, Brogi E:Sentinel lymph nodes for breast carcinoma:a paradigm shift. Arch Pathol Lab Med 140:791-798, 2016
21) van Diest PJ, Peterse HL, Borgstein PJ, et al:Pathological investigation of sentinel lymph nodes. Eur J Nucl Med 26(4 Suppl):S43-49, 1999
22) Weaver DL, Ashikaga T, Krag DN, et al:Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 364:412-421, 2011
23) Shiino S, Yoshida M, Jimbo K, et al:Two rare cases of endosalpingiosis in the axillary sentinel lymph nodes:evaluation of immunohistochemical staining and one-step nucleic acid amplification(OSNA) assay in patients with breast cancer. Virchows Arch 474:633-638, 2019
P.259 掲載の参考文献
1) 堀井理絵:乳癌における組織学的治療効果判定の意義と問題点. 病理と臨床35:1015-1019, 2017
2) 日本乳癌学会(編):乳癌診療ガイドライン1 治療編2018年版, 金原出版, 2018, pp12-17
3) 日本乳癌学会(編):乳癌診療ガイドライン2018年版, 追補2019, 金原出版, 2019, pp32-33
5) Van Eckyen E:Breast Tumours. in Brierley JD, Gospodarowicz MK, Wittekind C(eds):"TNM Classification of Malignant Tumours"(8th ed), John Wiley & Sons, Hoboken, 2017, pp151-158
6) 日本乳癌学会(編):臨床・病理 乳癌取扱い規約, 第18版, 金原出版, 2018, pp94-100
7) Yamaguchi T, Mukai H, Akiyama F, et al:Inter-observer agreement among pathologists in grading the pathological response to neoadjuvant chemotherapy in breast cancer. Breast Cancer 25:118-125, 2018
8) Fukada I, Araki K, Kobayashi K, et al:Pattern of tumor shrinkage during neoadjuvant chemotherapy is associated with prognosis in low grade luminal early breast cancer. Radiology 286:49-57, 2018
9) Kuroi K, Toi M, Ohno S, et al:Comparison of different definitions of pathologic complete response in operable breast cancer:a pooled analysis of three prospective neoadjuvant studies of JBCRG. Breast Cancer 22:586-595, 2015
10) Mukai H, Arihiro K, Shimizu C, et al:Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society. Breast Cancer 23:73-77, 2016
11) Kobayashi K, Horii R, Ito Y, et al:Prognostic significance of histological therapeutic effect in preoperative chemotherapy for breast cancer. Pathology Int 66:8-14, 2016
12) von Minckwitz G, Huang CS, Mano MS, et al:Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617-628, 2019
P.267 掲載の参考文献
1) Khatun N, Arihiro K, Inai K:Elastosis in breast-correlation with epithelial proliferation in benign disease and carcinomatous growth. Hiroshima J Med Sci 41:87-100, 1992
2) Suehiro S, Inai K, Tokuoka S, et al:Involvement of the nipple in early carcinoma of the breast. Surg Gynecol Obstet 168:244-248, 1989
3) Allison KH, Hammond MEH, Dowsett M, et al:Estrogen and progesterone receptor testing in breast cancer:ASCO/CAP guideline update. J Clin Oncol 38:1346-1366, 2020
4) Wolff AC, Hammond MEH, Allison KH, et al:Human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 36:2105-2122, 2018
5) Kensler KH, Regan MM, Heng YJ, et al:Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer:results from The Breast International Group Trial 1-98. Breast Cancer Res 21:30, 2019
6) Traina TA, Miller K, Yardley DA, et al:Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol 36:884-890, 2018
7) Lehmann BD, Jovanovic B, Chen X, et al:Refinement of triple-negative breast cancer molecular subtypes:implications for neoadjuvant chemotherapy selection. PLoS One 11:e0157368, 2016
8) Kumar S, Bal A, Das A, et al:Molecular subtyping of triple negative breast cancer by surrogate immunohistochemis-try markers. Appl Immunohistochem Mol Morphol 29:251-257, 2021
9) Cha YJ, Kim D, Bae SJ, et al:PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection. Sci Rep 11:19555, 2021
10) Pang JB, Castles B, Byrne DJ, et al:SP142 PD-L1 scoring shows high interobserver and intraobserver agreement in triple-negative breast carcinoma but overall low percentage agreement with other PD-L1 clones SP263 and 22C3. Am J Surg Pathol 45:1108-1117, 2021
11) Salgado R, Denkert C, Demaria S, et al:The evaluation of tumor-infiltrating lymphocytes(TILs) in breast cancer:recommendations by an International TILs Working Group 2014. Ann Oncol 26:259-271, 2015
12) Arihiro K, Kaneko M, Suehiro S, et al:Multicentric breast carcinoma:evaluation of clinicopathological and immunohistochemical characteristics. Breast Cancer 3:181-198, 1996
13) Diaz LK, Wiley EL, Venta LA:Are malignant cells displaced by large-gauge needle core biopsy of the breast? AJR Am J Roentgenol 173:1303-1313, 1999
14) Hoda SA:Ductal carcinoma in situ. in Hoda SA, Brogi E, Koerner FC, et al(eds):"Rosen's Breast Pathology"(5th ed. ), Wolters Kluwer, Philadelphia, 2021, pp363-450
15) Faverly DR, Burgers L, Bult P, et al:Three dimensional imaging of mammary ductal carcinoma in situ:clinical implications. Semin Diagn Pathol 11:193-198, 1994
16) Lester SC, Bose S, Chen YY, et al:Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med 133:15-25, 2009
17) Ellis I, Allison KH, Dang C, et al:Invasive Carcinoma of the Breast Histopathology Reporting Guide(2nd ed. V2.1), International Collaboration on Cancer Reporting, Sydney, 2022
18) Cserni G, Brogi E, Cody HS III, et al:Surgically Removed Lymph Nodes for Breast Tumours Histopathology Reporting Guide(1st ed. v1.1), International Collaboration on Cancer Reporting, Sydney, 2021

最近チェックした商品履歴

Loading...